@article {Ruiz-Ojeda2022.03.02.22271664, author = {Francisco Javier Ruiz-Ojeda and Augusto Anguita-Ruiz and Maria C. Rico and Rosaura Leis and Gloria Bueno and Mercedes Gil-Campos and {\'A}ngel Gil and Concepci{\'o}n M Aguilera}, title = {Serum levels of the novel adipokine isthmin-1 are associated with obesity in pubertal boys}, elocation-id = {2022.03.02.22271664}, year = {2022}, doi = {10.1101/2022.03.02.22271664}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Purpose The aims of this study were; 1) to evaluate if there is an association between the serum levels of the novel insulin-like adipokine isthmin-1 (ISM1) and obesity-related phenotypes in a population of Spanish children, 2) to investigate the plausible molecular alterations behind the alteration of the serum levels of this protein in children with obesity.Methods The study population is a sub-cohort of the PUBMEP research project, consisting of a cross-sectional population of 119 pubertal children with overweight (17 boys, 19 girls), obesity (20 boys, 25 girls) and normal weight (17 boys, 21 girls). All subjects were classified into experimental groups according to their sex, obesity and insulin resistance (IR) status. They counted on anthropometry, glucose, and lipid metabolism, inflammation and cardiovascular biomarkers as well as ISM1 serum levels measured. This population was intended as a discovery population in which to elucidate the relationship between obesity and ISM1 levels in children. Furthermore, the study population had blood whole-genome DNA methylation allowing deepening into the obesity-ISM1 molecular relationship.Results Higher serum levels of ISM1 were observed in boys with obesity when compared with normal-weight (P=0.004), and overweight (P=0.007). ISM1 serum levels were positively associated with BMI Z-score (P=0.005), and negatively with myeloperoxidase (MPO) (p=0.043) in boys. Nevertheless, we did not find associations between ISM1 serum levels and metabolic outcomes in girls, indicating a putative sexual dimorphism. DNA methylation levels in two-enhancer-related CpG sites of ISM1 (cg03304641 and cg14269097) were associated with serum levels of ISM1 in children.Discussion We report an unprecedented study that provides a major step forward showing that ISM1 is robustly associated with obesity in pubertal boys, elucidating how this protein might be of special relevance as a new biomarker of obesity in children.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Plan Nacional de Investigacion Cienti{\'o}ca, Desarrollo e Innovacion Tecnologica (I + D + I), Instituto de Salud Carlos III-Health Research Funding (FONDOS FEDER) (PI051968, PI1102042 and PI1600871); Redes tematicas de Investigacion cooperativa RETIC (Red SAMID RD12/0026/0015) and the Mapfre Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted according to the guidelines set out in the Declaration of Helsinki (Edinburgh 2000 revised), and all procedures were approved by the Ethics and Research Committee of Galicia Autonomous Community (2011/198 and 2016/522). Written consent was obtained from the parents of all the children.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsIRinsulin resistanceWCwaist circumferenceTNF-αtumour necrosis factor alphahsCRPhigh-sensitivity CRPILinterleukinPAI-1total plasminogen activator inhibitor-1MPOmyeloperoxidaseMCP-1monocyte chemoattractant protein 1MMP-9matrix metalloproteinase-9sICAM-1soluble intercellular cell adhesion molecule-1VCAMsoluble vascular cell adhesion molecule-1MLRmultiple linear regressionFDRfalse discovery rateLMElinear mixed-effectsISM1isthmin-1T2Dtype 2 diabetesMPOmyeloperoxidase.}, URL = {https://www.medrxiv.org/content/early/2022/03/04/2022.03.02.22271664}, eprint = {https://www.medrxiv.org/content/early/2022/03/04/2022.03.02.22271664.full.pdf}, journal = {medRxiv} }